High bax expression is a good prognostic indicator in acute myeloid leukaemia

British Journal of Haematology

Volumn 111, Issue 1, 2000, Pages 182-189

  Ong, Y L ^a   McMullin, M F ^a,b   Bailie, K E M ^b   Lappin, T R J ^a   Jones, F G C ^b   Irvine, A E ^a,c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Acute myeloid leukaemia; Bax; Bcl 2; Prognostic indicator; Spontaneous apoptosis

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RELAPSE; REMISSION; RISK ASSESSMENT; SURVIVAL;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME;

EID: 0033758957     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02315.x     Document Type: Article

References (24)

1. Bcl-2, bax and p53 expression in B-CLL in relation to in-vitro survival and clinical progression
2. Expression of Bcl-2-related genes in normal and AML progenitors: Changes induced by chemotherapy and retinoic acid
3. Measurement of spontaneous and therapeutic agent induced apoptosis wih bcl-2 expression in acute myeloid leukaemia
4. Expression of bax in relation to bcl-2 and other predictive parameters in breast cancer
5. Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression
6. High expression of bcl-2 protein in acute myeloid leukaemia cells is associated with poor response to chemotherapy
7. Apoptosis and a reinvestigation of the biologic basis for cancer therapy
8. Cell suicide in health and disease
9. Identification of programmed cell death in situ via specific labelling of nuclear DNA fragmentation
10. Inactivation of bcl-2 by phosphorylation
11. Apoptosis and the dilemma of cancer chemotherapy
12. Molecular mechanisms of drug resistance in tumours
13. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia
14. Reduced expression of pro-apoptotic gene bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma
15. Differential expression of apoptosis associated genes bax and bcl-2 in ovarian cancer
16. Hematopoietic malignancies demonstrate loss-of-function mutations of bax
17. Relation of apoptosis to cancer therapy
18. In situ apoptotic cell labeling by the TUNEL method: Improvement and evaluation on cell preparations
19. Baseline apoptosis of tumour cells as a response predictor to chemotherapy
20. Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome
21. Multiple Bcl-2 family members demonstrate selective dimerization with Bax
22. Association of bcl-2, bax, bcl-xL and interleukin-1-beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia
23. Cellular expression of anti-apoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: A Children's Cancer Group Study
24. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial